| Autor: |
Stamuli, Eugena, Corry, Sorcha, Ross, Derek, Konstantopoulou, Thomais, Texeira, Luis, Avouac, Bernard, Debiais, Dominique, Yates, Liz, Behis, Arni, McLoughlin, Ambrose, Stowarzyszeń Amazonki, Federacja, Niewada, Maciej, Casas, Ana, Espin, Jaime, Advisory board participants from France:, Advisory board participants from Ireland:, Advisory board participants from Poland:, Advisory board participants from Spain: |
| Zdroj: |
Future Oncology; Apr2022, Vol. 18 Issue 9, p1115-1132, 18p |
| Abstrakt: |
Aim: To understand breast cancer patients' trade-offs when choosing treatments and to identify the most important treatment attributes which drive decisions. Materials & methods: A discrete choice experiment was conducted in France, Ireland, Poland and Spain. Progression-free survival, febrile neutropenia, pain, functional well-being and out-of-pocket payment were the treatment attributes. Results: 371 patients were willing to pay €6896 per year for 1 additional year of progression-free survival, €17,288 per year for perfect functional well-being and €15,138 for one pain-free year. Patients are willing to trade off progression-free survival months for better functional abilities and less pain. Conclusion: Patient preferences should be considered by regulatory agencies, reimbursement bodies, payors and clinicians for best treatment choices for the individuals. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
